The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for advancing the development of new medical countermeasures against the biological agents that are most likely to be used in a terror attack on civilian populations. NIAID and the Biomedical Advanced Research and Development Authority are partnering to support the development of technologies and platforms for the development of therapeutics with either single-pathogen or broad spectrum activity against select NIAID Category A, B, and C bio- threat pathogens…
Recommended
Near Earth’s Unmanned Bell 505 Offering Picked For Marines’ Resupply Drone Development Effort
Trending
Congress Updates
Munitions Fired Represent Most of $25 Billion Spent By Pentagon on Iran War So Far
Munitions fired in the two-month old “Operation Epic Fury” against Iran represent most of the $25 billion cost the Pentagon has incurred thus far in the conflict, the acting Defense […]
Slotkin: Pentagon Should Use Anthropic’s Mythos To Spot Cyber Security Gaps
The Pentagon should be using Anthropic‘s recently announced Mythos artificial intelligence model to spot gaps in cyber security, Sen. Elissa Slotkin (D-Mich.) said on Tuesda. “I think the thing that […]
Budd And Shaheen Bill Would Authorize 329 F-15EX Fighters
Two members of the Senate Armed Services Committee (SASC), Sen. Ted Budd (R-N.C.) and Sen. Jeanne Shaheen (D-N.H.), have introduced the Airpower Acceleration Act, which would authorize multi-year procurements of […]
HASC’s Wittman Sees ‘Challenging’ Push For $350B In Reconciliation Funds, Wants Sustained Defense Increase
NATIONAL HARBOR, Md.– Congress’ work to pass $350 billion in reconciliation funds to support the Trump administration’s push for a $1.5 trillion fiscal year 2027 defense topline is “going to […]